drugset / Trial / NCT02486432

A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)

NCT02486432

Phase 1 Completed 6 enrolled NeuroDerm Ltd. Quotient Clinical · collab
NaSingle-groupOpen-label

Summary

A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) Doses Administered Using a Divided Dose Approach

Timeline

Start
2015-04
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbidopa Unknown 13.5 mg Oral
Subject Levodopa Small molecule 50 mg Oral

Indications